Preview

Rational Pharmacotherapy in Cardiology

Advanced search

APPLIED ASPECTS OF SLCO1B1 PHARMACOGENETIC TESTING FOR PREDICTING OF STATIN-INDUCED MYOPATHY AND PERSONALIZATION OF STATINS THERAPY

https://doi.org/10.20996/1819-6446-2013-9-6-698-700

Full Text:

Abstract

The clinical significance of the SLCO1B1 gene polymorphism (encoding an organic anion transport polipeptide) in the development of statin induced myopathy is considered. Possible tactics of statin dose determination on the basis of pharmacogenetic testing is discussed. Indications for the use of this approach in clinical practice that should increase the efficacy and safety of the statin therapy are also considered.

About the Authors

D. A. Sychev
Russian Medical Academy of Postgraduate Education, Center for Clinical Pharmacology, Research Center for Evaluation of Medical Products, Moscow
Russian Federation


G. N. Shuev
I.M. Sechenov First Moscow State Medical University, Moscow
Russian Federation


A. B. Prokofiev
Center for Clinical Pharmacology, Research Center for Evaluation of Medical Products, Moscow
Russian Federation


References

1. Riphagen IJ, van der Veer E, Muskiet FA, DeJongste MJ. Myopathy during statin therapy in the daily practice of an outpatient cardiology clinic: prevalence, predictors and relation with vitamin D. Curr Med Res Opin 2012;28(7):1247-52.

2. Pérez-Castrillón JL, Abad Manteca L, Vega G, et al. Vitamin d levels and lipid response to atorvastatin. Int J Endocrinol 2010;2010:3207-21.

3. Thompson PD, Parker BA, Clarkson PM, et al. A randomized clinical trial to assess the effect of statins on skeletal muscle function and performance: rationale and study design. Prev Cardiol 2010;13(3):104-11.

4. Hippisley-Cox J, Coupland C. Individualising the risks of statins in men and women in England and Wales: population-based cohort study. Heart 2010;96(12):939-47.

5. Link E, Parish S, Armitage J, et al., SEARCH Collaborative Group. SLCO1B1 variants and statin-induced myopathy a genomewide study. The New England Journal of Medicine 2008;359(8):789-99.

6. Voskoboynikov AM, Grachev AV, Knyazev GP, Sychev DA. Pharmacogenetic testing for allelic variants of SLCO1B1* 5: implications for personalization dosing of statins in patients with hyperlipidemia. Bulletin of Medical Internet Conference 2013; 3 (6): 975-6. Russian (Воскобойников А.М., Грачев А.В., Князева Г.П., Сычев Д.А. Фармакогенетическое тестирование по аллельному варианту SLCO1B1*5: значение для персонализации дозирования статинов у пациентов с гиперлипидемиями. Бюллетень Медицинских Интернет-конференций 2013; 3(6): 975-6).

7. Sirotkina AM, Khokhlov AL, Mogutova IS, et al. Prevalence of polymorphic marker gene SLCO1B1 in patients with hyperlipidemia and some polymorphic variants of genes in patients with hypertension. Science and modernity. Collected materials XXIV International extramural scientific-practical conference. 09.09.2013. Novosibirsk: NP SibAK, 2013: 90-6. Russian (Сироткина А.М., Хохлов А.Л., Мо- гутова И.С., и др. Распространенность полиморфного маркера гена SLCO1B1 у пациентов с гиперлипидемией и некоторых полиморфных вариантов генов у больных с артериальной гипертензией. Наука и современность. Сборник материалов XXIV Международной заочной научнопрактической конференции. 09.09.2013. Новосибирск: НП СибАК; 2013: 90-6).

8. Petrov VI, Smuseva ON, Solovkin YV. Comprehensive assessment of predictors of statin-associated muscle injury myschechnoy tissue in patients with coronary heart disease. Rational Pharmacother Card 2013, 9 (3): 247-50. Russian (Петров В.И., Смусева О.Н., Соловкина Ю.В. Комплексная оценка предикторов статин-ассоциированного мышечного поражения мыщечной ткани у пациентов с ишемической болезнью сердца. Рациональная Фармакотерапия в Кардиологии 2013;9 (3): 247-50).

9. Becquemont L, Alfirevic A, Amstutz U, et al. Pharmacogenomics. Practical recommendations for pharmacogenomics-based prescription: 2010 ESF-UB Conference on Pharmacogenetics and Pharmacogenomics. Pharmacogenomics 2011;12(1):113-24.

10. Musunuru K, Roden DM, Boineau R, et al. Cardiovascular pharmacogenomics: current status and future directions-report of a national heart, lung, and blood institute working group. J Am Heart As- soc2012;1(2):e000554.


For citation:


Sychev D.A., Shuev G.N., Prokofiev A.B. APPLIED ASPECTS OF SLCO1B1 PHARMACOGENETIC TESTING FOR PREDICTING OF STATIN-INDUCED MYOPATHY AND PERSONALIZATION OF STATINS THERAPY. Rational Pharmacotherapy in Cardiology. 2013;9(6):698-700. (In Russ.) https://doi.org/10.20996/1819-6446-2013-9-6-698-700

Views: 423


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)